Opinion: What It Means When Motherhood Means Peeing Yourself in Public
I'm watching my 8-year-old son try to con a nurse out of $500 by selling her a hunk of plastic he's labeled a 'blood diamond' when a mom next to me in the hospital waiting room leans over to ask: 'Is it the disease, you think?'
She's referring to adrenoleukodystrophy, the terrifying brain-devouring disease that her son shares with mine. 'Behavioral changes' are one of the tell-tale signs of its progression.
At this moment, though, I can safely say, 'No, my son's always been this way.'
Just moments earlier, a nurse who'd drawn his blood gave him a plastic coin with which to get himself a prize from a nearby toy machine. He pocketed the piece of plastic jewelry he'd won but returned to her looking downtrodden, whining, 'The machine ate my coin and didn't give me anything!'
'He's trying to scam you, don't fall for it!' I shouted from across the hall, my son unleashing a devilish grin as the nurse chuckled. The coin scam quickly turned into the 'blood diamond' scam with the gemstone he'd acquired and the other unsuspecting nurse further down the hall.
'Well he definitely seems to be doing better!' she says.
The last time this particular nurse had seen him, he'd asked to be euthanized. He was in the throes of chemo-induced agony, when no variation of 'this will be worth it in the end' could convince him that being brought to the brink of death really was his best chance at survival.
In less than three months, I've seen looks in his eyes that I'll never shake. I've watched him throw up blood. I've scrubbed up his puke and diarrhea with industrial-grade antiseptics so many times my hands have peeled and bled. I've sat through the night at his bedside and watched his chest rise and fall, so afraid that it might stop.
Countless other moms of sick children have gone through exactly the same thing. It sounds dramatic, but it requires little to no thinking—it's second nature, maybe even first. We call it motherhood, but I prefer to think it's one of those things that's too innate to have a name. Americans will celebrate that very unprofound national holiday in honor of this very profound thing this weekend, around the time my son and I find out if he has or has not been granted a reprieve from his childhood death sentence.
It will have special meaning for me.
In my case, it means watching my son turn around and smile at me and suddenly seeming, for one fleeting moment, to be cured of his deadly brain disease. And maybe he is. I feel a flush of warmth at the thought.
But then my legs give out and I crumple to the concrete floor like soggy cardboard and my son's expression changes as we both understand how much my own degenerative disease has progressed while his was being treated.
That is what it means to be a mother. Dying in slow motion to save your child.
I was told initially I could probably avoid ending up in a wheelchair. Diagnosed two years before my son's much scarier disease was detected, my autoimmune disease, multiple sclerosis, at first seemed like the biggest struggle our family would have to face.
'Avoid stress,' my neurologist had told me. 'Stress is the one thing we know will speed up progression. Get good sleep, eat healthy, exercise as much as you can and make whatever lifestyle changes you need to in order to minimize stress.'
I did as I was told, but a stress-free life wasn't in the cards. All that mattered in terms of my own illness when my son got sick was staving off progression long enough to ensure I could still be on my feet to tend to him as he underwent his bone marrow transplant.
'Just get him through it,' I told myself. 'We can't both be bedridden at the same time.'
I'm still not sure if it's funny or tragic that my son and I both wound up with degenerative diseases. I prefer to think my son's case is tragic, while mine is darkly humorous.
Like the time we were stuck in traffic, rushing to get him to a doctor's appointment for a test that would tell us if he was dying or not. It was the perfect time for the bladder issues caused by the lesions in my spine to remind me why I should never be too far from a toilet.
I peed myself in the car.
'It's me, not him. He's fine,' I responded brusquely to the looks of concern and queries about the stench of urine when we finally got to the hospital. (Loss of bladder control also happens to be a worrying milestone in my son's disease.)
As President Donald Trump flirts with the idea of 'baby bonuses' to boost the birth rate, I wonder if he's ever seen this side of parenting. If he's ever wet himself to put his child first. But of course that would be too much of a downer for his $5,000 gimmick and the White House lie that he 'wants America to be a country where all children can safely grow up and achieve the American dream.'
Not all children, let's be honest. Not the ones with cruel diseases that are too rare to matter to his administration. But mothers don't need a $5,000 cash incentive to fight for their kids. I'd gladly spend another 100 days scrubbing up my son's bile and holding his hand when he hurts, even as I stifle my own cries of pain. I'd do it all again, and then a thousand times more, and I'd do it until I died and then keep doing it from beyond the grave if it meant saving him.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
7 minutes ago
- Washington Post
Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation
NEW YORK — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week . They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a leading critic of pandemic-era lockdowns, and a professor of operations management.


Fast Company
22 minutes ago
- Fast Company
Enough hype about AI in health—let's talk about results
There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.


Medscape
27 minutes ago
- Medscape
Fast Five Quiz: Diffuse Large B-Cell Lymphoma
Although diffuse large B-cell lymphoma (DLBCL) is characterized by aggressive clinical behavior, standard treatment can provide good long-term survival outcomes. However, management can be complex, with certain comorbidities exacerbating disease severity and complications such as extranodal involvement significantly affecting prognosis. Understanding the nuances of DLCBL presentation, diagnosis, and management is key to delivering the best outcomes to patients affected by this rapidly progressive disease. What do you know about DLBCL? Check your knowledge with this quick quiz. Both primary and secondary Sjögren syndrome are strongly associated DLBCL. Other autoimmune disorders that have been associated with DLBCL include hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. In addition to autoimmune disorders, viral infections have also been linked to DLBCL; these include HIV, hepatitis B, hepatitis C, and Epstein-Barr. Further, data have shown that patients with rheumatic diseases have a heightened risk of DLBCL development. Though fugal or bacterial pneumonia, humoral deficiency, and bone infections (such as osteomyelitis) can occur in patients with DLBCL, data have indicated that survivors of DLBCL were more likely to experience these conditions, rather than being strongly linked to DLBCL itself. Learn more about DLBCL staging. In the NCCN's guidelines, PET/CT is the preferred modality for imaging in DLBCL workup. C/A/P CT with contrast can also be used in a complementary setting to help stage the disease and identify other factors such as extranodal disease or visceral involvement, but it is not preferred. Although not essential, head CT/MRI or neck CT/MRI with contrast (as well as bone marrow biopsy) can be useful for workup in selected cases. Specifically, bone marrow biopsy can be helpful in identifying indolent or low-volume disease. However, the NCCN notes that bone marrow biopsy is not needed if PET/CT shows bone disease. Learn more about DLBCL workup. Data indicate that extranodal involvement occurs in approximately 30%– 50% of patients with DLBCL; further, it is reported that gastrointestinal involvement is the most common extranodal site. Other affected sites include the skin, bones, spleen, and central nervous system; kidneys, testicles, and the liver can also be impacted, but they are not regarded as the most common. Learn more about DLCBL and extranodal involvement. A population-based study involving over 30,000 patients with extranodal DLBCL found that the best outcomes are associated with heart and mediastinal sites, with a 42% reduction in mortality risk compared with involvement of the intestinal tract. Involvement of the pancreas and hepatobiliary system, respiratory system, or nervous system are associated with significantly greater risks of mortality compared with the intestinal tract. Other factors associated with greater mortality risk include late age at onset, history of other malignancy, late age at presentation, and Black, non-Hispanic ethnicity. Learn more about DLBCL prognosis. CAR T therapy is typically utilized as a second-line treatment for patients with relapsed/refractory DLBCL. CD19-directed CAR T-cell therapy is considered ' the standard of care' for relapsed/refractory DLBCL, with three treatments approved for this population. Although a number of factors can lead to CAR T cell therapy resistance, the key mechanism is typically down regulation or loss of CD19 expression. Abnormal differentiation and dysfunction of T cells can also cause poor response to CAR T therapy, and being unable to collect enough T cells can also negatively affect the impact of CAR T products; however, these factors are not considered key mechanisms for resistance to CAR T-cell therapy. As such, early collection of T-cells in high-risk patients with DLBCL is one strategy to ensure enough T cells are available when needed. Partial response or relapse after CAR T therapy should prompt third-line therapy, such as alternative systemic therapy not previously given, clinical trial, palliative involved-site radiation therapy, or best supportive care. Learn more about relapsed or refractory DLBCL.